Tyrosine kinase-targeting drugs-associated heart failure

N. Gronich, I. Lavi, O. Barnett-Griness, W. Saliba, D. R. Abernethy, G. Rennert

Research output: Contribution to journalArticle

Abstract

Background:The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF).Methods:A nested case–control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-targeting, and/or chemotherapeutic drug, for a malignant disease, between 1 January 2005 and 31 December 2012. Each new case of HF was matched to up to 30 controls from the cohort on calendar year of cohort entry, age, gender, and duration of follow-up. Main outcome measure was odds ratio (OR) with 95% confidence interval (CI) of new-onset HF.Results:There were 936 incident cases of HF during 71 742 person-years of follow-up. Trastuzumab (OR 1.90, 95% CI 1.46–2.49), cetuximab (OR 1.72, 1.10–2.69), panitumumab (OR 3.01, 1.02–8.85), and sunitinib (OR 3.39, 1.78–6.47) were associated with increased HF risk. Comorbidity independently associated with higher risk in a multivariable conditional regression model was diabetes mellitus, hypertension, chronic renal failure, ischaemic heart disease, valvular heart disease, arrhythmia, and smoking.Conclusions:Trastuzumab, cetuximab, panitumumab, and sunitinib are associated with increased risk for new-onset HF.British Journal of Cancer advance online publication, 11 April 2017; doi:10.1038/bjc.2017.88 www.bjcancer.com.

LanguageEnglish (US)
JournalBritish Journal of Cancer
DOIs
StateAccepted/In press - Apr 11 2017
Externally publishedYes

Fingerprint

Drug Delivery Systems
Protein-Tyrosine Kinases
Heart Failure
Odds Ratio
Confidence Intervals
Neoplasms
Heart Valve Diseases
Chronic Kidney Failure
Health Services
Myocardial Ischemia
Survivors
Publications
Comorbidity
Cardiac Arrhythmias
Heart Diseases
Diabetes Mellitus
Smoking
Outcome Assessment (Health Care)
Hypertension
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gronich, N., Lavi, I., Barnett-Griness, O., Saliba, W., Abernethy, D. R., & Rennert, G. (2017). Tyrosine kinase-targeting drugs-associated heart failure. British Journal of Cancer. DOI: 10.1038/bjc.2017.88

Tyrosine kinase-targeting drugs-associated heart failure. / Gronich, N.; Lavi, I.; Barnett-Griness, O.; Saliba, W.; Abernethy, D. R.; Rennert, G.

In: British Journal of Cancer, 11.04.2017.

Research output: Contribution to journalArticle

Gronich, N, Lavi, I, Barnett-Griness, O, Saliba, W, Abernethy, DR & Rennert, G 2017, 'Tyrosine kinase-targeting drugs-associated heart failure' British Journal of Cancer. DOI: 10.1038/bjc.2017.88
Gronich N, Lavi I, Barnett-Griness O, Saliba W, Abernethy DR, Rennert G. Tyrosine kinase-targeting drugs-associated heart failure. British Journal of Cancer. 2017 Apr 11. Available from, DOI: 10.1038/bjc.2017.88
Gronich, N. ; Lavi, I. ; Barnett-Griness, O. ; Saliba, W. ; Abernethy, D. R. ; Rennert, G./ Tyrosine kinase-targeting drugs-associated heart failure. In: British Journal of Cancer. 2017
@article{0122512f1e8f4def9d38e78c1ca80450,
title = "Tyrosine kinase-targeting drugs-associated heart failure",
abstract = "Background:The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF).Methods:A nested case–control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-targeting, and/or chemotherapeutic drug, for a malignant disease, between 1 January 2005 and 31 December 2012. Each new case of HF was matched to up to 30 controls from the cohort on calendar year of cohort entry, age, gender, and duration of follow-up. Main outcome measure was odds ratio (OR) with 95\{%} confidence interval (CI) of new-onset HF.Results:There were 936 incident cases of HF during 71 742 person-years of follow-up. Trastuzumab (OR 1.90, 95\{%} CI 1.46–2.49), cetuximab (OR 1.72, 1.10–2.69), panitumumab (OR 3.01, 1.02–8.85), and sunitinib (OR 3.39, 1.78–6.47) were associated with increased HF risk. Comorbidity independently associated with higher risk in a multivariable conditional regression model was diabetes mellitus, hypertension, chronic renal failure, ischaemic heart disease, valvular heart disease, arrhythmia, and smoking.Conclusions:Trastuzumab, cetuximab, panitumumab, and sunitinib are associated with increased risk for new-onset HF.British Journal of Cancer advance online publication, 11 April 2017; doi:10.1038/bjc.2017.88 www.bjcancer.com.",
author = "N. Gronich and I. Lavi and O. Barnett-Griness and W. Saliba and Abernethy, {D. R.} and G. Rennert",
year = "2017",
month = "4",
day = "11",
doi = "10.1038/bjc.2017.88",
language = "English (US)",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Tyrosine kinase-targeting drugs-associated heart failure

AU - Gronich,N.

AU - Lavi,I.

AU - Barnett-Griness,O.

AU - Saliba,W.

AU - Abernethy,D. R.

AU - Rennert,G.

PY - 2017/4/11

Y1 - 2017/4/11

N2 - Background:The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF).Methods:A nested case–control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-targeting, and/or chemotherapeutic drug, for a malignant disease, between 1 January 2005 and 31 December 2012. Each new case of HF was matched to up to 30 controls from the cohort on calendar year of cohort entry, age, gender, and duration of follow-up. Main outcome measure was odds ratio (OR) with 95% confidence interval (CI) of new-onset HF.Results:There were 936 incident cases of HF during 71 742 person-years of follow-up. Trastuzumab (OR 1.90, 95% CI 1.46–2.49), cetuximab (OR 1.72, 1.10–2.69), panitumumab (OR 3.01, 1.02–8.85), and sunitinib (OR 3.39, 1.78–6.47) were associated with increased HF risk. Comorbidity independently associated with higher risk in a multivariable conditional regression model was diabetes mellitus, hypertension, chronic renal failure, ischaemic heart disease, valvular heart disease, arrhythmia, and smoking.Conclusions:Trastuzumab, cetuximab, panitumumab, and sunitinib are associated with increased risk for new-onset HF.British Journal of Cancer advance online publication, 11 April 2017; doi:10.1038/bjc.2017.88 www.bjcancer.com.

AB - Background:The impact of cancer therapies on cardiac disease in the general adult cancer survivor population is largely unknown. Our objective was to evaluate which tyrosine kinase-targeting drugs are associated with greater risk for new-onset heart failure (HF).Methods:A nested case–control analysis was conducted within a cohort of 27 992 patients of Clalit Health Services, newly treated with a tyrosine kinase-targeting, and/or chemotherapeutic drug, for a malignant disease, between 1 January 2005 and 31 December 2012. Each new case of HF was matched to up to 30 controls from the cohort on calendar year of cohort entry, age, gender, and duration of follow-up. Main outcome measure was odds ratio (OR) with 95% confidence interval (CI) of new-onset HF.Results:There were 936 incident cases of HF during 71 742 person-years of follow-up. Trastuzumab (OR 1.90, 95% CI 1.46–2.49), cetuximab (OR 1.72, 1.10–2.69), panitumumab (OR 3.01, 1.02–8.85), and sunitinib (OR 3.39, 1.78–6.47) were associated with increased HF risk. Comorbidity independently associated with higher risk in a multivariable conditional regression model was diabetes mellitus, hypertension, chronic renal failure, ischaemic heart disease, valvular heart disease, arrhythmia, and smoking.Conclusions:Trastuzumab, cetuximab, panitumumab, and sunitinib are associated with increased risk for new-onset HF.British Journal of Cancer advance online publication, 11 April 2017; doi:10.1038/bjc.2017.88 www.bjcancer.com.

UR - http://www.scopus.com/inward/record.url?scp=85017412686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017412686&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.88

DO - 10.1038/bjc.2017.88

M3 - Article

JO - British Journal of Cancer

T2 - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

ER -